Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
9.35
-0.85 (-8.33%)
At close: Sep 15, 2025, 4:00 PM EDT
9.37
+0.02 (0.21%)
After-hours: Sep 15, 2025, 4:10 PM EDT
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $965.00K in the quarter ending June 30, 2025, a decrease of -9.05%. This brings the company's revenue in the last twelve months to $3.17M, down -60.16% year-over-year. In the year 2024, Aligos Therapeutics had annual revenue of $3.95M, down -74.60%.
Revenue (ttm)
$3.17M
Revenue Growth
-60.16%
P/S Ratio
25.17
Revenue / Employee
$45,343
Employees
70
Market Cap
57.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.95M | -11.58M | -74.60% |
Dec 31, 2023 | 15.53M | 1.62M | 11.66% |
Dec 31, 2022 | 13.91M | 9.55M | 219.04% |
Dec 31, 2021 | 4.36M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALGS News
- 12 days ago - Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - GlobeNewsWire
- 13 days ago - Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 26 days ago - Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - GlobeNewsWire
- 4 weeks ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection - GlobeNewsWire
- 5 weeks ago - Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 3 months ago - Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) - GlobeNewsWire